Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06876857 · ClinicalTrials.gov registry record
University of Central Florida CereBank
A clinical trial of Brain Diseases and Brain Injury, sponsored by University of Central Florida.
- Recruiting
- Registry status
- 50,000
- Enrollment target
- 1
- Study location
NCT06876857: Recruiting study of Brain Diseases and Brain Injury, sponsored by University of Central Florida.
NCT06876857 is a study of Brain Diseases and Brain Injury that is actively recruiting participants, run by University of Central Florida. The registered enrollment target is 50,000 participants, above the 1,852-participant average among 12 other Brain Diseases trials with a reported enrollment target (2600% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06876857, a study of Brain Diseases and Brain Injury, is actively recruiting participants, sponsored by University of Central Florida.
- RECRUITING
- Registry status
- 50,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Millions of persons are affected by brain diseases. The CereBank will be used to support research studies aimed at improving the diagnosis and treatment of brain diseases. Brain diseases can be inherited; developed due to diseases or aging; or can be due to trauma. The Central Florida does not have a brain biobank to meet the needs of research. Therefore, it is necessary for the University of Central Florida to establish a brain biobank.
Primary Outcome
The UCF CereBank will be used to support research studies aimed at improving the diagnosis and treatment of brain diseases. Brain diseases can be inherited; developed due to diseases or aging; or can be due to trauma.
Conditions Studied
Study Locations (1)
Florida
- University of Central Florida - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50,000 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2075-02-25 |
What NCT06876857 shows while recruiting
NCT06876857 is an observational study that tracks outcomes without assigning an intervention. Its 50,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,852-participant average among 12 other Brain Diseases trials with a reported enrollment target (2600% higher).
The record links to 3 conditions, with Brain Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT06876857 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06876857 about?
NCT06876857 is a clinical study titled "University of Central Florida CereBank". Millions of persons are affected by brain diseases. The CereBank will be used to support research studies aimed at improving the diagnosis and treatment of brain diseases. Brain diseases can be inherited; developed due to diseases or aging; or can be due to trauma. The Central Florida does not have ...
What is the current status of trial NCT06876857?
This trial is currently recruiting. The enrollment target is 50,000 participants. The study started on 2025-02-25. Estimated completion is 2075-02-25.
What conditions does trial NCT06876857 study?
This clinical trial studies the following conditions: Brain Diseases, Brain Injury, Biospecimen Donation.
Who is sponsoring clinical trial NCT06876857?
This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06876857 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06876857's enrollment target sits among peer trials
50,000 1st of 12 higher than 12 of 12 other Brain Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RECRUITING · Phase 1
-
Amygdala Memory Enhancement
RECRUITING · NA
-
Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control
RECRUITING · NA
-
Metabolic and Hemodynamic Reserve in Pediatric SCA
RECRUITING · NA
-
Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)
ACTIVE NOT RECRUITING · NA
-
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00500123 · 50,000 participants
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
- NCT01885299 · 50,000 participants
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
- NCT03452774 · 50,000 participants
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- NCT04629586 · 50,000 participants
The T1D Exchange Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI